<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03318094</url>
  </required_header>
  <id_info>
    <org_study_id>162097</org_study_id>
    <nct_id>NCT03318094</nct_id>
  </id_info>
  <brief_title>Role of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity</brief_title>
  <official_title>Vanderbilt University Medical Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to better understand the contribution of sympathetic&#xD;
      vasoconstriction to impaired insulin-mediated vasodilation and subsequently insulin-mediated&#xD;
      glucose uptake. The investigators will test the hypothesis that removal of sympathetic&#xD;
      vasoconstriction can result in improvement in insulin-mediated vasodilation and subsequently&#xD;
      sensitivity to insulin-mediated glucose uptake.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several studies have shown that obese subjects have impaired Nitric Oxide (NO)-mediated&#xD;
      dilation; and those who develop insulin resistance tend to be more obese, have higher insulin&#xD;
      levels and greater sympathetic activity. Furthermore, we have made the novel observation that&#xD;
      autonomic blockade improves glucose utilization in obese subjects with insulin resistance,&#xD;
      providing a causal relation between sympathetic activation and insulin resistance. The&#xD;
      autonomic blockade also improved NO-mediated dilation in obese subjects, which may improve&#xD;
      glucose uptake by promoting glucose delivery.&#xD;
&#xD;
      The investigators will enroll obese insulin-resistant subjects and in parallel experiments&#xD;
      two comparator groups: obese insulin sensitive subjects, and healthy lean control subjects.&#xD;
      We will assess the effects of insulin (hyperinsulinemic euglycemic clamp) on microvascular&#xD;
      recruitment, and forearm glucose uptake on two separate occasions randomly assigned and at&#xD;
      least one month apart, during an intrabrachial infusion of the alpha-adrenergic blocker&#xD;
      phentolamine (blocked day) or saline control (Control day).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast Enhanced-Ultrasonography (CEU)</measure>
    <time_frame>Before clamp and 15 minutes after clamp</time_frame>
    <description>The Primary Outcome will be the change in CEU induced by insulin during hyperinsulinemic clamp compared to baseline. To test the null hypothesis that insulin will not produce any changes in microvascular blood volume using CEU in response to Î±-adrenergic blockade (phentolamine) in the isolated forearm model.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Healthy</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Intact Day</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blocked Day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phentolamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vasodilator Comparison</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium Nitroprusside</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentolamine</intervention_name>
    <description>Intrabrachial phentolamine will be given on the blocked day</description>
    <arm_group_label>Blocked Day</arm_group_label>
    <other_name>alpha-adrenergic blocker</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Intrabrachial saline will be given this day</description>
    <arm_group_label>Intact Day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Nitroprusside</intervention_name>
    <description>Intrabrachial sodium nitroprusside will be given this day to compare with phentolamine</description>
    <arm_group_label>Vasodilator Comparison</arm_group_label>
    <other_name>Active comparison</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females of all races between 18 and 60 years of age.&#xD;
&#xD;
          -  Obesity defined as body mass index between 30-40 kg/m2&#xD;
&#xD;
          -  Insulin resistance defined as homeostasis model assessment 2 insulin resistance&#xD;
             (HOMA2-IR) score &gt;1.6 (never diagnosed or treated type 2 diabetic), or being a&#xD;
             well-controlled type 2 diabetic on metformin only.&#xD;
&#xD;
          -  Able and willing to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Current smokers or history of heavy smoking (&gt;2 packs/day)&#xD;
&#xD;
          -  History of alcohol or drug abuse&#xD;
&#xD;
          -  Morbid obesity (BMI &gt; 40 kg/m2)&#xD;
&#xD;
          -  Previous allergic reaction to study medications&#xD;
&#xD;
          -  Evidence of type I diabetes.&#xD;
&#xD;
          -  Cardiovascular disease other than hypertension such as myocardial infarction within 6&#xD;
             months prior to enrollment, presence of angina pectoris, significant arrhythmia,&#xD;
             congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary&#xD;
             embolism, second or third-degree heart block, mitral valve stenosis, aortic stenosis,&#xD;
             or hypertrophic cardiomyopathy&#xD;
&#xD;
          -  History of serious cerebrovascular disease such as cerebral hemorrhage, stroke, or&#xD;
             transient ischemic attack&#xD;
&#xD;
          -  History or presence of immunological or hematological disorders&#xD;
&#xD;
          -  Impaired hepatic function [aspartate amino transaminase (AST) and/or alanine amino&#xD;
             transaminase (ALT) &gt; 2.0 x upper limit of normal range]&#xD;
&#xD;
          -  Impaired renal function (serum creatinine &gt;1.5 mg/dl)&#xD;
&#xD;
          -  Moderate to severe anemia (hemoglobin &lt;11 g/dl)&#xD;
&#xD;
          -  Treatment with serotonin-norepinephrine reuptake inhibitors (SNRIs) or norepinephrine&#xD;
             transporter (NET) inhibitors&#xD;
&#xD;
          -  Treatment with phosphodiesterase 5 inhibitors&#xD;
&#xD;
          -  Treatment with anticoagulants&#xD;
&#xD;
          -  Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days&#xD;
             in 1 month)&#xD;
&#xD;
          -  Treatment with any investigational drug in the 1 month preceding the study&#xD;
&#xD;
          -  Inability to give, or withdraw, informed consent&#xD;
&#xD;
          -  Other factors which in the investigator's opinion would prevent the subject from&#xD;
             completing the protocol (i.e., clinically significant abnormalities on clinical,&#xD;
             mental examination or laboratory testing or inability to comply with protocol)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Italo Biaggioni, MD</last_name>
    <phone>6159363420</phone>
    <email>autonomics@vanderbilt.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Autonomic Dysfunction Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Misty D Hale, CCRP</last_name>
      <phone>615-343-8649</phone>
      <email>autonomics@vanderbilt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jorge E Celedonio</last_name>
      <phone>6153223304</phone>
      <email>autonomics@vanderbilt.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>October 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Italo Biaggioni</investigator_full_name>
    <investigator_title>Professor Medicine and Pharmacology</investigator_title>
  </responsible_party>
  <keyword>insulin resistance</keyword>
  <keyword>phentolamine</keyword>
  <keyword>microvascular recruitment</keyword>
  <keyword>autonomic nervous system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroprusside</mesh_term>
    <mesh_term>Phentolamine</mesh_term>
    <mesh_term>Adrenergic alpha-Antagonists</mesh_term>
    <mesh_term>Adrenergic Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

